INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ANALYSIS

India Active Pharmaceutical Ingredients Market, By Manufacturer (Captive AP I and Merchant API), By Synthesis Type (Synthetic and Biotech), By Drug Type (Generic and Branded), By Application (Cardiology, Oncology, Pulmonology, Neurology, Orthopedic, Ophthalmology, and Other), By Product Type (Low Potent APIs and High Potent APIs), By Formulation (Oral, Topical, Parenteral, Drops, and Others)

In February 2023, Aurobindo Pharma Limited , a Pharmaceutical company is pleased to announce that its step-down subsidiary, Aurolife Pharma LLC, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Diclofenac Sodium Topical Solution USP, 2% w/w.
In July 2022, Piramal Pharma Limited’s Pharma Solutions division, a top Contract Development and Manufacturing Organization (CDMO), opened a new active pharmaceutical ingredient (API) plant at its Aurora, Ontario location.
In March 2022, India initiated domestic production of 35 active pharmaceutical ingredients, which had previously been 90% dependent on imports from China, as part of the production-linked incentives (PLI) scheme.